Science Highlights
Published on November 02, 2026
HCT Outcomes in Patients With Lymphoma and HIV
by Transplantation and Cellular Therapy
David KA, Brunson A, Schonfeld SJ, et al. Differences in Hematopoietic Cell Transplantation Outcomes by Human Immunodeficiency Virus Status, California, 1991 to 2016. Transplantation and Cellular Therapy. 2026; (doi: 10.1016/j.jtct.2026.08.049).
Potentially curative hematopoietic cell transplantation (HCT) is viable for eligible individuals with lymphoma and HIV, based on a retrospective review of California patients meeting this clinical profile from 1991 to 2016. Researchers searched multiple registries and databases to identify a sample population of 140 adult HCT recipients with first primary lymphoma plus HIV and 409 matched controls without HIV. Hospitalization and length of stay were compared between the two cohorts. At 90 days post-transplant, patients with HIV were no more likely than those without the virus to experience acute renal and liver complications, infections, or sepsis. They were also not at any greater risk for hospitalization and had similar lengths of stay as patients without HIV. Overall survival (OS) was comparable between the two groups at 90 days, reaching 94% for patients with HIV and 93% for those without HIV. This narrow difference persisted over time, with OS rates of 78% vs. 73%, respectively, at 1 year, and 73% vs. 69%, respectively, at 2 years.
Read more.
![]()
Transplantation and Cellular Therapy